Healthcare >> CEO Interviews >> June 18, 2001
DR. PAUL AVERBACK is the Founder, CEO and President of Nymox
Pharmaceutical Corporation. He is the inventor of Nymox's spheron
technologies and the co-inventor with other scientists of many of
Nymox's proprietary technologies. Dr. Averback has a vast experience as
a successful independent entrepreneur, scientific researcher, medical
specialist, and front-line practitioner, and he has successfully
negotiated several strategic research collaborations with large
multinational pharmaceutical companies in the US, Europe and Japan. Dr.
Averback has extensive firsthand knowledge of health care, with
positions including emergency room physician, family physician, clinic
administrator and university medical faculty member. In addition to many
issued and pending patents, Dr. Averback has published prolifically in
peer review literature on subjects including pharmaceuticals,
Alzheimer's disease, diagnostics, oncology, cytology, neuroanatomy,
neuropathology, geometrical probability, embryology, morphometry,
congenital disease, vascular disease, and others, including a
significant list of worldwide first discoveries in many fields. Dr.
Averback (MD 1975) holds a Diploma of the American Board of Pathology
with Special Competence in Neuropathology, was a Medical Research
Council Postdoctoral Fellow at Cambridge University (1977-1980) and was
on the Faculty of Medicine at McGill University (1980-1985). Profile
TWST: We'd like to begin with a general summary and overview of NymoxPharmaceutical Corporation ' a description of the company and business
today, a short history of the company and some